Akebia Therapeutics, Inc. (AKBA)
AKBA Stock Price Chart
Explore Akebia Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AKBA price movements and trends.
AKBA Company Profile
Discover essential business fundamentals and corporate details for Akebia Therapeutics, Inc. (AKBA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Mar 2014
Employees
181.00
Website
https://www.akebia.comCEO
John Butler
Description
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA Financial Timeline
Browse a chronological timeline of Akebia Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.03, while revenue estimate is $48.85m.
Earnings released on 7 May 2026
EPS came in at -$0.03 falling short of the estimated -$0.01 by -200.00%, while revenue for the quarter reached $53.54m , beating expectations by +3.63%.
Earnings released on 26 Feb 2026
EPS came in at -$0.05 falling short of the estimated -$0.03 by -66.67%, while revenue for the quarter reached $57.62m , beating expectations by +25.01%.
Earnings released on 10 Nov 2025
EPS came in at $0.00 surpassing the estimated -$0.06 by +103.28%, while revenue for the quarter reached $58.77m , beating expectations by +21.49%.
Earnings released on 7 Aug 2025
EPS came in at $0.00 surpassing the estimated -$0.02 by +104.55%, while revenue for the quarter reached $62.47m , beating expectations by +30.45%.
Earnings released on 8 May 2025
EPS came in at $0.03 surpassing the estimated -$0.03 by +200.00%, while revenue for the quarter reached $57.34m , beating expectations by +12.87%.
Earnings released on 13 Mar 2025
EPS came in at -$0.10 falling short of the estimated -$0.05 by -100.00%, while revenue for the quarter reached $46.50m , beating expectations by +24.28%.
Earnings released on 7 Nov 2024
EPS came in at -$0.10 falling short of the estimated -$0.05 by -100.00%, while revenue for the quarter reached $37.43m , missing expectations by -8.51%.
Earnings released on 8 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $43.65m , missing expectations by -11.73%.
Earnings released on 9 May 2024
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $32.61m , missing expectations by -34.06%.
Earnings released on 14 Mar 2024
EPS came in at $0.00 surpassing the estimated $0.00 by +100.00%, while revenue for the quarter reached $56.20m , beating expectations by +1.46%.
Earnings released on 8 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $42.05m , missing expectations by -24.30%.
Earnings released on 25 Aug 2023
EPS came in at -$0.06 falling short of the estimated -$0.03 by -140.00%, while revenue for the quarter reached $56.38m , missing expectations by -4.61%.
Earnings released on 8 May 2023
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%, while revenue for the quarter reached $40.13m , missing expectations by -14.04%.
Earnings released on 9 Mar 2023
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $55.18m , beating expectations by +16.41%.
Earnings released on 3 Nov 2022
EPS came in at -$0.28 falling short of the estimated -$0.15 by -86.67%, while revenue for the quarter reached $48.96m , beating expectations by +0.17%.
Earnings released on 4 Aug 2022
EPS came in at $0.23 surpassing the estimated -$0.31 by +174.19%, while revenue for the quarter reached $126.76m , beating expectations by +139.03%.
Earnings released on 9 May 2022
EPS came in at -$0.35 falling short of the estimated -$0.27 by -29.63%, while revenue for the quarter reached $61.70m , beating expectations by +39.37%.
Earnings released on 1 Mar 2022
EPS came in at -$0.40 falling short of the estimated -$0.33 by -21.21%, while revenue for the quarter reached $59.61m , beating expectations by +15.13%.
Earnings released on 4 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%, while revenue for the quarter reached $48.76m , beating expectations by +3.06%.
Earnings released on 5 Aug 2021
EPS came in at -$0.51 falling short of the estimated -$0.30 by -70.00%, while revenue for the quarter reached $52.91m , beating expectations by +34.68%.
AKBA Stock Performance
Access detailed AKBA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
